Business Description
Bright Minds Biosciences is a US-based biotech company focused on developing new treatments for serious neurological and psychiatric conditions, including epilepsy, developmental brain disorders, and Prader Willi Syndrome. The company has several drug candidates at various stages of clinical testing, with its lead program BMB-101 currently in Phase 2 trials. Founded in 2017 and based in New York, Bright Minds works with partners such as Firefly Neuroscience to support its ongoing research.
